Immunotherapy for Head and Neck Cancer: Where do We Go from Here?
Immunotherapy · 2023
DOI: 10.2217/imt-2023-0191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Eric C Ko und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Massachusetts Chan Medical School, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA…. Hauptthemen laut MEDLINE: Head and Neck Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Bicara, BMS and Regeneron.
Abstract (Originalsprache)
Tweetable abstract Immunotherapy for head and neck cancer shows promising new directions - and challenges ahead. What can we learn from recent trials to improve patient selection and optimize combination therapy?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Massachusetts Chan Medical School, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA.
- Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
ORCID-Profile: Eric C Ko
Förderung
- Bicara, BMS and Regeneron
Zitieren
APA
Ko, E. C., & Hanna, G. J. (2023). Immunotherapy for Head and Neck Cancer: Where do We Go from Here?. Immunotherapy. https://doi.org/10.2217/imt-2023-0191
Vancouver
Ko EC, Hanna GJ. Immunotherapy for Head and Neck Cancer: Where do We Go from Here?. Immunotherapy. 2023. doi:10.2217/imt-2023-0191
BibTeX
@article{Ko2023,
author = {Ko, Eric C and Hanna, Glenn J},
title = {Immunotherapy for Head and Neck Cancer: Where do We Go from Here?},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2023-0191}
}
EUVIMED